Skin toxicity of enfortumab vedotin: Proposal of a specific management algorithm

Saskia Ingen-Housz-Oro^{1

2

3}, Yannick S Elshot^{3

4

5}, Sonia Segura^{3

6}, Antoine Marchand^{3

7}, Damien Pouessel⁸, Nicolas Kluger^{3

9}, Giselle de Barros Silva^{3

10}, Ariadna Ortiz-Brugues^{3

8}, Marine Aubert¹¹, Carolina Saldana^{11

12}, Dimitrios Mavroudis¹³, Estelle Burle⁸, Emilie Tournier¹⁴, Dimitra Koumaki^{3

15}, Vincent Sibaud^{3

8}

Affiliations

¹ Dermatology Department, AP-HP, Henri Mondor Hospital, Univ Paris Est Créteil EpiDermE, Créteil, France.
² Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.
³ Dermatology for Cancer Patients EADV Task Force, Toulouse, France.
⁴ Department of Dermatology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
⁵ Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
⁶ Dermatology Department, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, Barcelona, Spain.
⁷ Dermatology Unit, Department of Medicine, Gustave Roussy Cancer Campus, Villejuif, France.
⁸ Oncology Department, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
⁹ Dermatology Department, Helsinki University Hospital, Helsinki, Finland.
¹⁰ Dermatology Department, Hospital 12 de Octubre, Madrid, Spain.
¹¹ Oncology Department, AP-HP, Henri Mondor Hospital, Créteil, France.
¹² Univ Paris Est Creteil, TRePCa, Créteil, France.
¹³ Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece.
¹⁴ Department of Pathology, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
¹⁵ Department of Dermatology and Venereology, University Hospital of Heraklion, Crete, Greece.

Saskia Ingen-Housz-Oro et al. J Eur Acad Dermatol Venereol. 2024 Jan.

. 2024 Jan;38(1):e99-e101.

doi: 10.1111/jdv.19454. Epub 2023 Aug 29.

¹ Dermatology Department, AP-HP, Henri Mondor Hospital, Univ Paris Est Créteil EpiDermE, Créteil, France.
² Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.
³ Dermatology for Cancer Patients EADV Task Force, Toulouse, France.
⁴ Department of Dermatology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
⁵ Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
⁶ Dermatology Department, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, Barcelona, Spain.
⁷ Dermatology Unit, Department of Medicine, Gustave Roussy Cancer Campus, Villejuif, France.
⁸ Oncology Department, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
⁹ Dermatology Department, Helsinki University Hospital, Helsinki, Finland.
¹⁰ Dermatology Department, Hospital 12 de Octubre, Madrid, Spain.
¹¹ Oncology Department, AP-HP, Henri Mondor Hospital, Créteil, France.
¹² Univ Paris Est Creteil, TRePCa, Créteil, France.
¹³ Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece.
¹⁴ Department of Pathology, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
¹⁵ Department of Dermatology and Venereology, University Hospital of Heraklion, Crete, Greece.

No abstract available

References

1. Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384:1125-1135.
1. Lacouture ME, Patel AB, Rosenberg JE, O'Donnell PH. Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin. Oncologist. 2022;27:e223-e232.
1. Guerrois F, Thibault C, Lheure C, Sohier P, Bensaid B, Ingen-Housz-Oro S, et al. Life-threatening skin reaction with enfortumab vedotin: six cases. Eur J Cancer. 2022;167:168-171.
1. Apalla Z, Nikolaou V, Fattore D, Fabbrocini G, Freites-Martinez A, Sollena P, et al. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force ‘dermatology for cancer patients’ position statement. J Eur Acad Dermatol Venereol. 2022;36:332-350.
1. Ingen-Housz-Oro S, Milpied B, Badrignans M, Carrera C, Elshot YS, Bensaid B, et al. Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases. Melanoma Res. 2022;32:205-210.